Intensity Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Intensity Therapeutics, Inc. has issued its 2026 proxy statement detailing proposals for director elections, equity plan amendments, and auditor ratification.
NASDAQ
Intensity Therapeutics, Inc. has filed definitive additional materials related to its proxy statement pursuant to Section 14(a) of the Securities Exchange Act of 1934.
NASDAQ
Intensity Therapeutics, Inc. is seeking stockholder approval for a reverse stock split to meet Nasdaq's minimum bid price requirement and improve marketability.
NASDAQ
Intensity Therapeutics, Inc. has filed definitive additional materials with the U.S. Securities and Exchange Commission, supplementing its previously filed proxy statement.
NASDAQ
Intensity Therapeutics, Inc. has announced its 2025 annual meeting of stockholders will be held virtually on July 17, 2025, to elect one director and ratify the appointment of EisnerAmper LLP as its independent registered public accounting firm.
NASDAQ
Intensity Therapeutics has filed definitive additional materials related to its proxy statement with the SEC.
NASDAQ
Intensity Therapeutics is holding its 2024 annual meeting to elect directors, approve an employee stock purchase plan, and ratify its accounting firm.